Superworth

Editas Medicine revenue EDIT

Sales by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
$47M
Latest quarter, Q2 FY26
$11.9M
+232% on a year earlier
Fiscal year 2025
$40.5M
+25% on the year before

Editas Medicine's revenue was $47M over the twelve months to Jun 30, 2026, up 21% on a year earlier.

In its latest quarter, Q2 FY26, it was $11.9M, up 232% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 15% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$40.5M+25%
FY2024$32.3M−59%
FY2023$78.1M+296%
FY2022$19.7M−23%
FY2021$25.5M−72%
FY2020$90.7M+342%
FY2019$20.5M−36%
FY2018$31.9M+133%
FY2017$13.7Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$11.9M+232%$47M
Q1 FY26$2.8M−39%$38.7M
Q4 FY25$24.7M−19%$40.5M
Q3 FY25$7.5M+12266%$46.4M
Q2 FY25$3.6M+597%$38.9M
Q1 FY25$4.7M+310%$35.8M
Q4 FY24$30.6M−49%$32.3M
Q3 FY24$61K−99%$61.8M
Q2 FY24$513K−82%$67M
Q1 FY24$1.1M−88%$69.4M
Q4 FY23$60M+819%$78.1M
Q3 FY23$5.3M+12605%$24.6M

Against its peers

Companies in Biotechnology nearest Editas Medicine's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
EDITEditas Medicine$47M+21% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
MGTXMeiraGTx$397.5M
VCELVericel$306.3M+23% a year
ADMAAdma Biologics$512.3M+8% a year
Peer median$351.9M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Editas Medicine

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.